Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

Notable examples include the Pfizer-BioNTech and Moderna vaccines, which rely on lipid nanoparticles (LNPs) for mRNA protection and cellular uptake, and hepatitis B vaccines, which use virus-like ...

Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax ® and, where applicable, additional Moderna products that Moderna ... company with world-class platforms, a robust ...

The "mRNA Cancer Therapeutics Patent Landscape Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com ...

The door may now be open for additional challenges to patents covering mRNA vaccine technologies, paving the way for increased competition in the ...

According to court documents, the lawsuits focus on Moderna's use of lipid nanoparticle encapsulation of mRNA vaccines, a technology used to protect the mRNA molecules as they are delivered to ...